Dexamethasone as risk-factor for ICU-acquired respiratory tract infections in severe COVID-19.

ABSTRACT:

Purpose

Dexamethasone is the only drug that has consistently reduced mortality in patients with COVID-19, especially in patients needing oxygen or invasive mechanical ventilation. However, there is a growing concern about the relation of dexamethasone with the unprecedented rates of ICU-acquired respiratory tract infections (ICU-RTI) observed in patients with severe COVID-19.

Methods

This was a multicenter, prospective cohort study; conducted in ten countries in Latin America and Europe. We included patients older than 18 with confirmed SARS-CoV-2 requiring ICU admission. A multivariate logistic regression and propensity score matching (PSM) analysis was conducted to determine the relation between dexamethasone treatment and ICU-RTI.

Results

A total of 3777 patients w

SUBMITTER: Reyes LF 

PROVIDER: S-EPMC8863516 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature